Evidence map›Paper›PMID 34148963›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.

Keita Kawakado, Tomoki Tamura, Masamoto Nakanishi, Go Makimoto, Shoichi Kuyama

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Keita KawakadoDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan.
Tomoki TamuraDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan.
Masamoto NakanishiDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan.
Go MakimotoDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan.
Shoichi KuyamaDepartment of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan.
Iwakuni Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab is a monoclonal antibody with anti-tumor effects. Only a few reports have previously described retrobulbar optic neuritis induced by pembrolizumab. We herein report the case of a 63-year-old man with advanced lung adenocarcinoma who received cisplatin, pemetrexed, and pembrolizumab combination therapy for six months. Following treatment, a visual field test showed a left central scotoma. Imaging studies showed left optic neuritis without brain metastasis. Blood tests showed an elevated serum creatinine level. He was diagnosed with retrobulbar optic neuritis and pembrolizumab-induced renal failure. After receiving corticosteroid treatment, his renal function rapidly improved. The optic neuritis improved somewhat, but it was not adequately resolved.

Indexed as

Adenocarcinoma of LungLung NeoplasmsOptic NeuritisAntibodies, Monoclonal, HumanizedHumansMaleMiddle AgedAntibodies, Monoclonal, Humanizedpembrolizumabnon-small-cell lung cancerpembrolizumabretrobulbar optic neuritis

Identifiers

PMID34148963
PMCPMC8758449
OpenAlexW3173772370

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.